CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
Open Access
- 22 August 2021
- journal article
- review article
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 12 (3) , 476-489
Abstract
Immunotherapy has become a prominent strategy for the treatment of cancer. A method that improves the immune system’s ability to attack a tumor (Enhances antigen binding). Targeted killing of malignant cells by adoptive transfer of chimeric antigen receptor (CAR) T cells is a promising immunotherapy technique in the treatment of cancers. For this purpose, the patient’s immune cells, with genetic engineering aid, are loaded with chimeric receptors that have particular antigen binding and activate cytotoxic T lymphocytes. That increases the effectiveness of immune cells and destroying cancer cells. This review discusses the basic structure and function of CAR-T cells and how antigenic targets are identified to treat different cancers and address the disadvantages of this treatment for cancer.Keywords
This publication has 131 references indexed in Scilit:
- Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological SynapseJournal of Immunology Research, 2013
- Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groupsHaematologica, 2012
- Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomideInternational Journal of Oncology, 2012
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCRBlood, 2012
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric ReceptorMolecular Therapy, 2012
- Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008